Egetis Therapeutics AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	63.1	62.4	46.1	57.6	22.6	38.2
Revenue	63.1	62.4	46.1	57.6	22.6	38.2
Revenue Growth (YoY)	35.12%	35.36%	-19.96%	154.87%	-40.84%	-6.05%
Cost of Revenue	54.1	50	11.6	11	142.6	96.6
Gross Profit	9	12.4	34.5	46.6	-120	-58.4
Selling, General & Admin	218.3	201	215.3	172.8	74.3	44.6
Research & Development	156.7	158.3	146.2	194	-	-
Other Operating Expenses	-7.9	-16.9	-5.2	-8.9	-	-0.3
Operating Expenses	367.1	342.4	356.3	357.9	77	46.8
Operating Income	-358.1	-330	-321.8	-311.3	-197	-105.2
Interest Expense	-9.7	-14.4	-17.6	-4.2	-0.1	-0.2
Interest & Investment Income	5.2	5.2	6.9	4.9	0.9	0.1
Currency Exchange Gain (Loss)	-10.3	-10.3	-6.3	-13.4	2.4	0.6
Other Non Operating Income (Expenses)	-0.8	7.4	-4.5	-2.8	-	0.2
Pretax Income	-373.7	-342.1	-343.3	-326.8	-193.8	-104.5
Income Tax Expense	0.4	0.4	0.3	0.1	-	-
Net Income	-374.1	-342.5	-343.6	-326.9	-193.8	-104.5
Net Income to Common	-374.1	-342.5	-343.6	-326.9	-193.8	-104.5
Shares Outstanding (Basic)	377	368	307	257	194	180
Shares Outstanding (Diluted)	377	373	311	260	194	180
Shares Change (YoY)	16.70%	20.10%	19.57%	33.86%	7.97%	166.96%
EPS (Basic)	-0.99	-0.93	-1.12	-1.27	-1.00	-0.58
EPS (Diluted)	-0.99	-0.93	-1.12	-1.30	-1.00	-0.60
Free Cash Flow	-264.8	-267	-227.9	-278.4	-173.5	-130.3
Free Cash Flow Per Share	-0.70	-0.71	-0.73	-1.07	-0.89	-0.72
Gross Margin	14.26%	19.87%	74.84%	80.90%	-	-152.88%
Operating Margin	-567.51%	-528.85%	-698.05%	-540.45%	-871.68%	-275.39%
Profit Margin	-592.87%	-548.88%	-745.34%	-567.53%	-857.52%	-273.56%
Free Cash Flow Margin	-419.65%	-427.89%	-494.36%	-483.33%	-767.70%	-341.10%
EBITDA	-356.63	-328.6	-320.7	-310.2	-195.8	-104
EBITDA Margin	-	-	-	-	-	-272.25%
D&A For EBITDA	1.48	1.4	1.1	1.1	1.2	1.2
EBIT	-358.1	-330	-321.8	-311.3	-197	-105.2
EBIT Margin	-	-	-	-	-	-275.39%
Revenue as Reported	-	-	-	-	22.6	38.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.